-transparent.png){kind=logo}
In ten patients with heterozygous familial hypercholesterolaemia, combination therapy with cholestyramine and nicotinic acid was instituted for a minimum of 2 months. During therapy, plasma low-density lipoprotein levels were reduced by 32%, and low-density lipoprotein to high-density lipoprotein ratios by 40%. The cholesterol saturation of fasting gall-bladder bile was reduced by 33% during treatment. We conclude that long-term combination therapy with cholestyramine and nicotinic acid is practically feasible in heterozygous familial hypercholesterolaemia, normalizes plasma cholesterol and low-density lipoprotein levels in many patients, and does not result in unwanted side-effects on biliary lipids. It should therefore be considered as the therapy of choice in this condition.
B Angelin, and
M Eriksson, and
K Einarsson
July 1988,
BMJ (Clinical research ed.),
B Angelin, and
M Eriksson, and
K Einarsson
February 1981,
Lancet (London, England),
B Angelin, and
M Eriksson, and
K Einarsson
March 1990,
Gut,
B Angelin, and
M Eriksson, and
K Einarsson
July 1994,
Digestive diseases and sciences,
B Angelin, and
M Eriksson, and
K Einarsson
November 1995,
Gut,
B Angelin, and
M Eriksson, and
K Einarsson
May 1992,
BMJ (Clinical research ed.),
B Angelin, and
M Eriksson, and
K Einarsson
May 1973,
Archives of disease in childhood,
B Angelin, and
M Eriksson, and
K Einarsson
April 1988,
Lancet (London, England),
B Angelin, and
M Eriksson, and
K Einarsson
December 1977,
European journal of clinical investigation,
B Angelin, and
M Eriksson, and
K Einarsson
January 1992,
European journal of clinical pharmacology,
